Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06811038 · ClinicalTrials.gov registry record · Phase 3
iCanQuit Smoking Cessation Among Hispanic Adults
A Phase 3 study, sponsored by Fred Hutchinson Cancer Center.
- Not yet
- Registry status
- Phase 3
- Development phase
- 854
- Enrollment target
NCT06811038: Clinical Trial Phase 3 study, sponsored by Fred Hutchinson Cancer Center.
NCT06811038 is a Phase 3 study that has not yet begun recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 854 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06811038, a Phase 3 study, has not yet begun recruiting, sponsored by Fred Hutchinson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 854 participants
- Enrollment target
Study Summary
This phase III trial compares a smartphone application with or without nicotine replacement therapy in improving smoking cessation among Hispanic adults who would like to quit smoking. The iCanQuit smartphone application focuses on skills for managing urges, motivation, and relapse prevention with personalized quit plans. Nicotine replacement therapy works by giving small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking without any of the other harmful chemicals found in tobacco products.
Primary Outcome
The comparison will use a logistic regression model, following standard intent-to-treat analysis for smoking cessation trials, will be employed, coding all missing outcomes as smoking. The model will adjust for stratification factors and baseline factors that are both imbalanced after randomization and significantly related to the outcome.
Interventions
- OTHER Survey Administration
- DRUG Nicotine Patch
- DRUG Nicotine Lozenge
- DRUG Nicotine Gum
- DEVICE iCanQuit Smartphone App Smoking Cessation Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 2026-08-15 |
| Est. Completion | 2030-07-01 |
| Phase | Phase 3 |
What is known before NCT06811038 opens enrollment
NCT06811038 is an interventional study that assigns participants to a tested intervention. The registered 854 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 5 interventions - of which Survey Administration is the first listed.
NCT06811038 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06811038 about?
NCT06811038 is a clinical study titled "iCanQuit Smoking Cessation Among Hispanic Adults". This phase III trial compares a smartphone application with or without nicotine replacement therapy in improving smoking cessation among Hispanic adults who would like to quit smoking. The iCanQuit smartphone application focuses on skills for managing urges, motivation, and relapse prevention with p...
What is the current status of trial NCT06811038?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 854 participants. The study started on 2026-08-15. Estimated completion is 2030-07-01.
What interventions are being tested in trial NCT06811038?
The interventions under investigation include: Survey Administration (OTHER), Nicotine Patch (DRUG), Nicotine Lozenge (DRUG), Nicotine Gum (DRUG), iCanQuit Smartphone App Smoking Cessation Program (DEVICE).
Who is sponsoring clinical trial NCT06811038?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06811038's enrollment target sits among peer trials
854 384th of 2000 higher than 1,616 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
- NCT06231485 · 856 participants · NA
Socialization To Enrich Participation & Support Sexuality for Young People With I/DD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI